WWL113
WWL113 性质
| 沸点 | 630.9±55.0 °C(Predicted) |
|---|---|
| 密度 | 1?+-.0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMF：25mg/mL； DMF:PBS(pH7.2)(1:2)：0.3mg/ml； DMSO：15mg/mL；乙醇：0.1mg/mL |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 5.18±0.26(Predicted) |
| 颜色 | 白色至米白色 |
WWL113 用途与合成方法
IC50: 120 nM (Ces3), 100 nM (Ces1f).
Ces3 and Ces1f are endoplasmic reticulum glycoproteins that have been previously associated with adipocyte lipolysis. WWL113 inhibits mouse recombinant Ces1, Ces1c, and ABHD6 at 10 μM.
WWL113 (1 μM) significantly increases UCP1 protein expression in brown adipocytes.
WWL113 has a partial, statistically significant inhibitory effect on blocking the buildup of PGE2.
WWL113 (30 mg/kg, orally once a day) results in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance.
WWL113 ameliorates obesity-diabetes in mice.
| Animal Model: | Eight-week-old db/db mice (n = 10 per group). |
| Dosage: | 30 mg/kg. |
| Administration: | Orally once a day for 3 weeks. |
| Result: | Corrected multiple features of metabolic syndrome in db/db mice. |
WWL113 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-110148 | WWL113 | 947669-86-5 | 5 mg | 800 |
| 2024-11-08 | HY-110148 | 10 mM * 1 mLin DMSO | 820 |
